Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Author(s): Ligia Mendes Soares, Jos Prickaerts, Humberto Milani, Elaine Del Bel, Harry Wilhelm Maria Steinbusch, Rubia Maria Weffort de Oliveira

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 14 , Issue 8 , 2015

Become EABM
Become Reviewer


Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

Keywords: Animal models, brain ischemia, stroke, phosphodiesterase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1012 - 1023]
Pages: 12
DOI: 10.2174/1871527314666150909114249
Price: $65

Article Metrics

PDF: 21